Back to results
US 8,278,294 B2Granted
Substituted isoquinoline and isoquinolinone derivatives as inhibitors of Rho-kinase
AssigneeSanofi
InventorsOliver Plettenburg, Armin Hofmeister, Joachim Brendel, Matthias Lohn
Life of this patent
Estimating the term…
Abstract
The invention relates to 6-substituted isoquinoline and isochinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
Claims7
A compound of the formula (I)
- wherein
- R1 is OH;
- R2 is H, halogen or (C1-C6)alkyl;
- R3 is
- H,
- halogen,
- (C1-C6)alkyl,
- (C1-C6)alkylene-R′,
- OH,
- O—R″,
- NH2,
- NHR″,
- NR″R″ or
- NH—C(O)—R″,
- R4 is
- H,
- halogen,
- hydroxy,
- CN,
- (C1-C6)alkyl,
- R′,
- (C1-C6)alkylene-R′;
- R5 is
- H,
- halogen,
- CN,
- NO2,
- (C1-C6)alkyl,
- (C2-C6)alkenyl,
- R′,
- (C1-C6)alkylene-(C6-C10)aryl,
- (C2-C6)alkenylene-(C6-C10)aryl,
- (C1-C6)alkylene-(C5-C10)heterocyclyl,
- CH(OH)—(C1-C6)alkyl,
- NH2,
- NH—R′,
- NH—SO2H,
- NH—SO2—(C1-C6)alkyl,
- NH—SO2—R′,
- NH—C(O)—(C1-C6)alkyl,
- NH—C(O)—R′,
- C(O)N[(C1-C6)alkyl]2,
- C(O)OH, or
- C(O)O—(C1-C6)alkyl;
- R6 is
- (C1-C6)alkylene-C(O)NH—(C1-C6)alkyl,
- (C1-C6)alkylene-C(O)N[(C1-C6)alkyl]2,
- C(O)(C1-C6)alkyl,
- C(O)(C3-C8)cycloalkyl,
- C(O)—(C5-C10)heterocyclyl,
- C(O)(C1-C6)alkylene-(C3-C8)cycloalkyl,
- C(O)(C1-C6)alkylene-(C5-C10)heterocyclyl, or
- C(O)(C1-C6)alkylene-(C6-C10)aryl
- R7 is
- H,
- halogen,
- CN,
- NO2,
- (C1-C6)alkyl,
- O—(C1-C6)alkyl,
- (C2-C6)alkenyl,
- R′,
- (C2-C6)alkenylene-(C6-C10)aryl,
- (C1-C6)alkylene-R′,
- CH(OH)—(C1-C6)alkyl,
- NH2,
- NH—R′,
- NH—SO2H,
- NH—SO2—(C1-C6)alkyl,
- NH—SO2—R′,
- SO2—NH2,
- SO2—NHR′,
- NH—C(O)—(C1-C6)alkyl,
- NH—C(O)—R′,
- C(O)N[(C1-C6)alkyl]2,
- C(O)OH, or
- C(O)O—(C1-C6)alkyl;
- R8 is H, halogen or (C1-C6)alkyl;
- n is 1, 2, 3 or 4;
- m is 1, 2, 3, 4 or 5;
- L is O or O—(C1-C6)alkylene;
- R′ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl;
- R″ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C6)alkyl,
- (C1-C6)alkylene-R′,
- (C1-C6)alkylene-O—(C1-C6)alkyl,
- (C1-C6)alkylene-O—R′, or
- (C1-C6)alkylene-NRxRy;
- and
- Rx and Ry are independently of each other
- (C1-C6)alkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C4)alkylene-(C5-C10)heterocyclyl,
- (C1-C4)alkylene-(C6-C10)aryl,
- (C1-C4)alkylene-NH(C1-C6)alkyl,
- (C1-C4)alkylene-N[(C1-C6)alkyl]2,
- (C1-C4)alkylene-N[(C6-C10)aryl]2, or
- (C1-C4)alkylene-N[(C5-C10)heterocyclyl]2;
- wherein in residues R4, R5, R6, R7 and R8 as alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONHCH3 or CON(CH3)2;
- wherein in residues R2 to R8 as alkyl or alkylene can optionally be substituted one or more times by halogen;
- wherein in residues R3 to R8 as (C6-C10)aryl and (C5-C10)heterocyclyl are unsubstituted or substituted one or more times by a suitable group independently selected from halogen, OH, NO2, N3, CN, C(O)—(C1-C6)alkyl, C(O)—(C1-C6)aryl, COOH, COO(C1-C6)alkyl, CONH2, CONH(C1-C6)alkyl, CON[(C1-C6)alkyl]2, (C3-C8)cycloalkyl, (C1-C6)alkyl, (C1-C6)alkylene-OH, (C1-C6)alkylene-NH2, (C1-C6)alkylene-NH(C1-C6)alkyl, (C1-C6)alkylene-N[(C1-C6)alkyl]2, (C2-C6)alkenyl, (C2-C6)alkynyl, O—(C1-C6)alkyl, O—C(O)—(C1-C6)alkyl, PO3H2, SO3H, SO2—NH2, SO2NH(C1-C6)alkyl, SO2N[(C1-C6)alkyl]2, S—(C1-C6)alkyl;
- SO—(C1-C6)alkyl, SO2—(C1-C6)alkyl, SO2—N═CH—N[(C1-C6)alkyl]2, C(NH)(NH2), NH2, NH—(C1-C6)alkyl, N[(C1-C6)alkyl]2, NH—C(O)—(C1-C6)alkyl, NH—C(O)O—(C1-C6)alkyl, NH—SO2—(C1-C6)alkyl, NH—SO2(C6-C10)aryl, NH—SO2—(C5-C10)heterocyclyl, N(C1-C6)alkyl-C(O)—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)O—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)—NH—(C1-C6)alkyl], (C6-C10)aryl, (C1-C6)alkylene-(C6-C10)aryl, O—(C6-C10)aryl, O—(C1-C6)alkylene-(C6-C10)aryl, (C5-C10)heterocyclyl, (C1-C6)alkylene-(C5-C10)heterocyclyl, and O—(C1-C6)alkylene-(C5-C10)heterocyclyl,
- wherein the (C6-C10)aryl or (C5-C10)heterocyclylin the substituent may be substituted one to three times by a group independently selected from halogen, OH, NO2, CN, O—(C1-C6)alkyl, (C1-C6)alkyl, NH2, NH(C1-C6)alkyl, N[(C1-C6)alkyl]2, SO2CH3, COOH, C(O)O—(C1-C6)alkyl, CONH2, (C1-C6)alkylene-O—(C1-C6)alkyl, (C1-C6)alkylene-O—(C6-C10)aryl, and O—(C1-C6)alkylene-(C6-C10)aryl;
- or
- wherein (C6-C10)aryl is vicinally substituted by a O—(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to;
- and
- wherein aryl substituent of (C6-C10)aryl and (C5-C10)heterocyclyl substituent groups may not be further substituted by an aryl or heterocyclyl containing group;
- or stereoisomeric form thereof and/or tautomeric form thereof and/or pharmaceutically acceptable salt thereof.
112 more elements
A compound of the formula (I)
- wherein
- R1 is OH;
- R2 is H, halogen or (C1-C6)alkyl;
- R3 is H, halogen, (C1-C4)alkylene-R′, O—R″ or NHR″;
- R4 is H, halogen or (C1-C6)alkyl;
- R5 is H, (C1-C6)alkyl, halogen, CN, (C2-C6)alkenyl, (C6-C10)aryl, NH—(C6-C10)aryl, (C1-C6)alkylene-(C6-C10)aryl, (C5-C10)heterocyclyl or (C1-C6)alkylene-(C5-C10)heterocyclyl;
- R6 is (C1-C6)alkylene-C(O)N[(C1-C4)alkyl]2, C(O)(C1-C6)alkyl, C(O)(C3-C8)cycloalkyl, C(O)(C1-C6)alkylene-C3-C8)cycloalkyl, C(O)(C1-C6)alkylene-C5-C10)heterocyclyl, or C(O)(C1-C6)alkylene-(C6-C10)aryl;
- R7 is H, halogen, CN, (C1-C6)alkyl, O—(C1-C6)alkyl, (C2-C6)alkenyl or R′;
- R8 is H, halogen or (C1-C6)alkyl;
- m is 2, 3 or 4
- n is 1, 2 or 3, and
- L is O, O-methylene or O-ethylene
- R′ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl;
- R″ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C6)alkyl,
- (C1-C6)alkylene-R′,
- (C1-C6)alkylene-O—(C1-C6)alkyl,
- (C1-C6)alkylene-O—R′, or
- (C1-C6)alkylene-NRxRy;
- and
- Rx and Ry are independently of each other
- (C1-C6)alkyl, (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C4)alkylene-(C5-C10)heterocyclyl,
- (C1-C4)alkylene-(C6-C10)aryl,
- (C1-C4)alkylene-NH(C1-C6)alkyl,
- (C1-C4)alkylene-N[(C1-C6)alkyl]2,
- (C1-C4)alkylene-N[(C6-C10)aryl]2, or
- (C1-C4)alkylene-N[(C5-C10)heterocyclyl]2;
- wherein in residues R4, R5, R6, R7 and R8 as alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONHCH3 or CON(CH3)2;
- wherein in residues R2 to R8 as alkyl or alkylene can optionally be substituted one or more times by halogen;
- wherein in residues R3 to R8 as (C6-C10)aryl and (C5-C10)heterocyclyl are unsubstituted or substituted one or more times by a suitable group independently selected from halogen, OH, NO2, N3, CN, C(O)—(C1-C6)alkyl, C(O)—(C1-C6)aryl, COOH, COO(C1-C6)alkyl, CONH2, CONH(C1-C6)alkyl, CON[(C1-C6)alkyl]2, (C3-C8)cycloalkyl, (C1-C6)alkyl, (C1-C6)alkylene-OH, (C1-C6)alkylene-NH2, (C1-C6)alkylene-NH(C1-C6)alkyl, (C1-C6)alkylene-N[(C1-C6)alkyl]2, (C2-C6)alkenyl, (C2-C6)alkynyl, O—(C1-C6)alkyl, O—C(O)—(C1-C6)alkyl, PO3H2, SO3H, SO2—NH2, SO2NH(C1-C6)alkyl, SO2N[(C1-C6)alkyl]2, S—(C1-C6)alkyl;
- SO—(C1-C6)alkyl, SO2—(C1-C6)alkyl, SO2—N═CH—N[(C1-C6)alkyl]2, C(NH)(NH2), NH2, NH—(C1-C6)alkyl, N[(C1-C6)alkyl]2, NH—C(O)—(C1-C6)alkyl, NH—C(O)O—(C1-C6)alkyl, NH—SO2—(C1-C6)alkyl, NH—SO2—(C6-C10)aryl, NH—SO2-(C5-C10)heterocyclyl, N(C1-C6)alkyl-C(O)—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)O—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)—NH—(C1-C6)alkyl], (C6-C10)aryl, (C1-C6)alkylene-(C6-C10)aryl, O—(C6-C10)aryl, O—(C1-C6)alkylene-(C6-C10)aryl, (C5-C10)heterocyclyl, (C1-C6)alkylene-(C5-C10)heterocyclyl, and O—(C1-C10)alkylene-(C5-C10)heterocyclyl,
- wherein the (C6-C10)aryl or (C5-C10)heterocyclyl in the substituent may be substituted one to three times by a group independently selected from halogen, OH, NO2, CN, O—(C1-C6)alkyl, (C1-C6)alkyl, NH2, NH(C1-C6)alkyl, N[(C1-C6)alkyl]2, SO2CH3, COOH, C(O)O—(C1-C6)alkyl, CONH2, (C1-C6)alkylene-O—(C1-C6)alkyl, (C1-C6)alkylene-O—(C6-C10)aryl, and O—(C1-C6)alkylene-(C6-C10)aryl;
- or
- wherein (C6-C10)aryl is vicinally substituted by a O—(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to;
- and
- wherein aryl substituent of (C6-C10)aryl and (C5-C10)heterocyclyl substituent groups may not be further substituted by an aryl or heterocyclyl containing group;
- or stereoisomeric form thereof and/or tautomeric form thereof and/or pharmaceutically acceptable salt thereof.
42 more elements
A compound of the formula (I)
- wherein;
- R1 is OH;
- R2 is (C1-C4)alkyl;
- R3 is H, halogen or NHR″;
- R4 is H, halogen or (C1-C4)alkyl;
- R5 is H, (C1-C6)alkyl, halogen, (C2-C4)alkenyl, (C6-C10)aryl, (C1-C6)alkylene-(C6-C10)aryl or (C5-C10)heterocyclyl;
- R6 is C(O)(C1-C6)alkyl, C(O)(C3-C8)cycloalkyl, C(O)—(C5-C10)heterocyclyl, C(O)(C1-C6)alkylene-(C3-C8)cycloalkyl, C(O)(C1-C6)alkylene-(C5-C10)heterocyclyl, or C(O)(C1-C6)alkylene-(C6-C10)aryl;
- R7 is H, halogen, CN, (C1-C6)alkyl, O—(C1-C6)alkyl, (C2-C6)alkenyl or R′;
- R8 is H, halogen or (C1-C6)alkyl;
- m is 2, 3 or 4
- n is 1, 2 or 3;
- and
- L is O
- R′ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl;
- R″ is
- (C3-C8)cycloalkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C6)alkyl,
- (C1-C6)alkylene-R′,
- (C1-C6)alkylene-O—(C1-C6)alkyl,
- (C1-C6)alkylene-O—R′, or
- (C1-C6)alkylene-NRxRy;
- and
- Rx and Ry are independently of each other
- (C1-C6)alkyl,
- (C5-C10)heterocyclyl,
- (C6-C10)aryl,
- (C1-C4)alkylene-(C5-C10)heterocyclyl,
- (C1-C4)alkylene-(C6-C10)aryl,
- (C1-C4)alkylene-NH(C1-C6)alkyl,
- (C1-C4)alkylene-N[(C1-C6)alkyl]2,
- (C1-C4)alkylene-N[(C6-C10)aryl]2, or
- (C1-C4)alkylene-N[(C5-C10)heterocyclyl]2;
- wherein in residues R4, R5, R6, R7 and R8 as alkyl, alkylene or cycloalkyl can optionally be substituted one or more times by OH, OCH3, COOH, COOCH3, NH2, NHCH3, N(CH3)2, CONHCH3 or CON(CH3)2;
- wherein in residues R2 to R8 as alkyl or alkylene can optionally be substituted one or more times by halogen;
- wherein in residues R3 to R8 as (C6-C10)aryl and (C5-C10)heterocyclyl are unsubstituted or substituted one or more times by a suitable group independently selected from halogen, OH, NO2, N3, CN, C(O)—(C1-C6)alkyl, C(O)—(C1-C6)aryl, COOH, COO(C1-C6)alkyl, CONH2, CONH(C1-C6)alkyl, CON[(C1-C6)alkyl]2, (C3-C8)cycloalkyl, (C1-C6)alkyl, (C1-C6)alkylene-OH, (C1-C6)alkylene-NH2, (C1-C6)alkylene-NH(C1-C6)alkyl, (C1-C6)alkylene-N[(C1-C6)alkyl]2, (C2-C6)alkenyl, (C2-C6)alkynyl, O—(C1-C6)alkyl, O—C(O)—(C1-C6)alkyl, PO3H2, SO3H, SO2—NH2, SO2NH(C1-C6)alkyl, SO2N[(C1-C6)alkyl]2, S—(C1-C6)alkyl;
- SO—(C1-C6)alkyl, SO2—(C1-C6)alkyl, SO2—N═CH—N[(C1-C6)alkyl]2, C(NH)(NH2), NH2, NH—(C1-C6)alkyl, N[(C1-C6)alkyl]2, NH—C(O)—(C1-C6)alkyl, NH—C(O)O—(C1-C6)alkyl, NH—SO2—(C1-C6)alkyl, NH—SO2—(C6-C10)aryl, NH—SO2-(C5-C10)heterocyclyl, N(C1-C6)alkyl-C(O)—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)O—(C1-C6)alkyl, N(C1-C6)alkyl-C(O)—NH—(C1-C6)alkyl], (C6-C10), aryl, (C1-C6)alkylene-(C6-C10)aryl, O—(C6-C10)aryl, O—(C1-C6)alkylene-(C6-C10)aryl, (C5-C10)heterocyclyl, (C1-C6)alkylene-(C5-C10)heterocyclyl, and O—(C1-C6)alkylene-(C5-C10)heterocyclyl,
- wherein the (C6-C10)aryl or (C5-C10)heterocyclyl in the substituent may be substituted one to three times by a group independently selected from halogen, OH, NO2, CN, O—(C1-C6)alkyl, (C1-C6)alkyl, NH2, NH(C1-C6)alkyl, N[(C1-C6)alkyl]2, SO2CH3, COOH, C(O)O—(C1-C6)alkyl, CONH2, (C1-C6)alkylene-O—(C1-C6)alkyl, (C1-C6)alkylene-O—(C6C10)aryl, and O—(C1-C6)alkylene-(C6-C10)aryl;
- or
- wherein (C6-C10)aryl is vicinally substituted by a O—(C1-C4)alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to and wherein aryl substituent of (C6-C10)aryl and (C5-C10)heterocyclyl substituent groups may not be further substituted by am aryl or heterocyclyl containing group;
- or stereoisomeric form thereof and/or tautomeric form thereof and/or pharmaceutically acceptable salt thereof.
42 more elements
A compound of the formula (I)
- wherein;
- R1 —OH;
- R2 is H, or (C1-C4)alkyl;
- R3 is H, NH—(C5-C6)heteroaryl or NH-phenyl;
- R4 is H, halogen or (C1-C4)alkyl;
- R5 is H, (C1-C4)alkyl, halogen, (C2-C4)alkenyl, (C6-C10)aryl, (C1-C2)alkyl-(C6-C10)aryl or (C5-C6)heteroaryl;
- R6 is C(O)(C1-C6)alkyl,
- C(O)(C3-C8)cycloalkyl, C(O)—(C5-C10)heterocyclyl,
- C(O)(C1-C3)alkylene-(C5-C10)heterocyclyl or C(O)(C1-C3)alkylene-(C6-C10)aryl;
- R7 is H, halogen, CN, (C1-C4)alkyl, O—(C1-C4)alkyl, (C2-C4)alkenyl, phenyl, cyclopropyl, (C5-C6)heteroaryl;
- R8 is H, halogen or (C1-C4)alkyl;
- m is 3;
- n is 1;
- and
- L is O
- or stereoisomeric form thereof and/or tautomeric form thereof and/or pharmaceutically acceptable salt thereof.
13 more elements
A compound selected from the group consisting of:
- and a stereoisomeric form, a tautomeric form and a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.